- Home
- KPRX vs POLA Comparison
KPRX vs POLA Comparison
Compare KPRX & POLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- POLA
- Stock Information
- Founded
- KPRX 1998
- POLA 1979
- Country
- KPRX United States
- POLA United States
- Employees
- KPRX N/A
- POLA N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- POLA Industrial Machinery/Components
- Sector
- KPRX Health Care
- POLA Miscellaneous
- Exchange
- KPRX Nasdaq
- POLA Nasdaq
- Market Cap
- KPRX 10.0M
- POLA 8.3M
- IPO Year
- KPRX N/A
- POLA 2016
- Fundamental
- Price
- KPRX $3.91
- POLA $3.27
- Analyst Decision
- KPRX Strong Buy
- POLA
- Analyst Count
- KPRX 1
- POLA 0
- Target Price
- KPRX $10.00
- POLA N/A
- AVG Volume (30 Days)
- KPRX 54.6K
- POLA 75.4K
- Earning Date
- KPRX 11-08-2024
- POLA 11-14-2024
- Dividend Yield
- KPRX N/A
- POLA N/A
- EPS Growth
- KPRX N/A
- POLA N/A
- EPS
- KPRX 1.69
- POLA N/A
- Revenue
- KPRX $16,020,000.00
- POLA $14,953,000.00
- Revenue This Year
- KPRX N/A
- POLA $6.72
- Revenue Next Year
- KPRX N/A
- POLA N/A
- P/E Ratio
- KPRX $2.31
- POLA N/A
- Revenue Growth
- KPRX N/A
- POLA N/A
- 52 Week Low
- KPRX $3.00
- POLA $2.24
- 52 Week High
- KPRX $8.98
- POLA $4.90
- Technical
- Relative Strength Index (RSI)
- KPRX 60.98
- POLA 54.57
- Support Level
- KPRX $3.10
- POLA $3.09
- Resistance Level
- KPRX $4.00
- POLA $3.48
- Average True Range (ATR)
- KPRX 0.25
- POLA 0.41
- MACD
- KPRX 0.02
- POLA 0.01
- Stochastic Oscillator
- KPRX 90.00
- POLA 32.32
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About POLA Polar Power Inc.
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications primarily in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, Back-up DC generators, hybrid power systems, Li-Ion battery systems, and Marine DC generators. The Companie's geographical presence is in the United States, Canada, Mexico, South Pacific Islands, Japan, Europe and Middle East and Other Asia Pacific countries.